To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: T80/A5/H12.5 FDC
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 676
- Registration Number
- NCT03021265
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT03017885
- Locations
- 🇮🇳
Action Cancer Hospital, Delhi, Delhi, India
🇮🇳Apollo Health City Hospital, Hyderabad, India
🇮🇳Chittaranjan National Cancer Institute, Kolkata, India
Validation of Predictors of OAC Initiation Using EMR Data
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 140187
- Registration Number
- NCT03006341
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 306
- Registration Number
- NCT03003494
- Locations
- 🇮🇹
Ospedale Generale Regionale "Miulli", Acquaviva Delle Fonti (BA), Italy
🇮🇹Azienda Ospedaliera G. Rummo, Benevento, Italy
🇮🇹Casa di cura Mons. Calaciura, Biancavilla, Italy
To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT03004404
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Ibuprofen/Caffeine Lower Back or Neck Pain Study
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 635
- Registration Number
- NCT03003000
- Locations
- 🇩🇪
Praxis Dr. Steinebach, Essen, Essen, Germany
🇩🇪Praxis Dr. Pabst, Gilching, Gilching, Germany
🇩🇪Praxis Dr. Klein, Künzing, Künzing, Germany
Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BI 1467335 (Treatment C)Drug: BI 1467335 (Treatment A)Drug: BI 1467335 (Treatment B)
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02999191
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 663
- Registration Number
- NCT02999178
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇧🇪ULB Hopital Erasme, Bruxelles, Belgium
Treatment Pattern of Oral Anticoagulants (OAC) in Japan
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48696
- Registration Number
- NCT02982863
- Locations
- 🇯🇵
NISED Center, Tokyo, Shinagawa, Japan
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02978690
- Locations
- 🇲🇾
Hospital Sultanah Aminah, Johor Bahru, Malaysia
🇫🇷HOP Saint-Louis, Paris, France
🇰🇷Pusan National Univ. Hosp, Busan, Korea, Republic of